ALLENA PHARMACEUTICALS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)

Published: 2021-09-29 08:44:13 ET ALNA

Item 8.01 Other Information

On September 29, 2021, Allena Pharmaceuticals, Inc. issued a press release to report that it has dosed the first patient in a second Phase 2a trial of ALLN-346, a novel, orally-administered, urate-degrading enzyme in development for the treatment of gout in patients with chronic kidney disease. A copy of the press release is filed herewith as Exhibit 99.1 to this Report on Form 8-K and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

--------------------------------------------------------------------------------